Direct compression screening of sulphamethoxypyridazine base at API loadings above 65% w/w produces tablets with pronounced capping and lamination tendencies, attributable to the crystalline API's high elastic recovery and low plasticity index. The preferred manufacturing route for immediate-release oral tablets therefore employs wet granulation in a high-shear granulator (GEA PMA 300 or equivalent) using purified water as the granulation liquid, with polyvinylpyrrolidone K30 at 2.0–5.0% w/w of the final core mass dissolved to form the binder solution. Granulation end-point is determined by impeller torque and product temperature (22–28°C), followed by fluid bed drying (Glatt GPCG 30 or equivalent) at inlet air temperature 55–65°C until loss-on-drying of the dried granules measures 1.5–2.5% w/w by halogen moisture analyzer. Dry milling through a conical mill fitted with a 1.0–1.5 mm rasping screen and 1500–2500 rpm rotor speed yields granules with Carr index 18–22% and Hausner ratio 1.18–1.25, suitable for rotary tablet compression at 30–60 rpm turret speed on a Korsch XL 400 or Fette 3090i press. Compression force of 8–15 kN across a 13 mm round flat-faced beveled-edge tooling set produces cores with hardness 80–120 N measured by a Schleuniger hardness tester and friability ≤0.8% after 100 revolutions in a Pharmatron friabilator. The core formulation typically contains the API at 55–75% w/w, lactose monohydrate or microcrystalline cellulose PH102 at 15–30% w/w, croscarmellose sodium or sodium starch glycolate at 2.0–4.0% w/w, PVP K30 at 2.0–5.0% w/w, and magnesium stearate at 0.5–1.5% w/w added by final blending for 3–5 minutes in a bin blender at 12–15 rpm. The pharmaceutical quality framework comprising USP ‹711› Dissolution Apparatus 2 (paddle, 50–75 rpm, 900 mL medium) and USP ‹905› Uniformity of Dosage Units applies to each production batch, with dissolution acceptance criteria of Q = 75% at 45 minutes in 0.1 N hydrochloric acid or pH 6.8 phosphate buffer depending upon the target regulatory submission. In-process control for blend uniformity is performed per 21 CFR 211.110(a) using near-infrared spectroscopy or stratified sample assay with acceptance limits of 90.0–110.0% label claim and relative standard deviation ≤5.0%. Elemental impurity testing follows ICH Q3D (R2) with daily intake limits for Class 1 elements (As, Cd, Hg, Pb) assessed against the maximum daily dose. Tablet core weight for a 500 mg strength product falls within 670–830 mg, with the final dosage form delivered as uncoated scored tablets or film-coated tablets using an aqueous hydroxypropyl methylcellulose coating system applied in a perforated side-vented pan coater (Glatt Coater GC 750 or equivalent) to a weight gain of 2.0–4.0% w/w. Terminal finished product types include 250 mg and 500 mg sulphamethoxypyridazine tablets, marketed as antibacterial monotherapy for urinary tract and respiratory tract infections where regional prescribing patterns retain long-acting sulfonamides.

What Limits Powder Flow in Low-Density Sulfonamide Capsule Filling?

Encapsulation of sulphamethoxypyridazine base into hard gelatin capsules requires particle size control because milled API with a median particle size below 75 µm exhibits cohesive flow behavior and bridging in the hopper of volumetric capsule filling equipment. The API is blended with lactose monohydrate (spray-dried grade) or mannitol at 30–45% w/w, the sulphamethoxypyridazine base comprising 40–60% w/w of the fill mass, together with croscarmellose sodium 3.0–5.0% w/w, colloidal silicon dioxide 0.5–1.0% w/w, and magnesium stearate 0.5–1.0% w/w by total blend weight. Sieving of the API and major excipients through a 30–40 mesh (approximately 425–600 µm aperture) stainless steel sieve precedes blending in a bin blender at 12–15 rpm for 15–20 minutes, with lubricant added separately for the final 3–5 minutes to minimize shear-induced hydrophobic film formation on the sulfonamide crystal surfaces. The blend is charged to a dosing disc or dosator-type capsule filling machine (MG2 Compact 8 or Bosch GKF 1500) operating at 8,000–15,000 capsules/hour for size 0 or size 00 hard gelatin capsules. Fill weight control is achieved through automated weight checking with rejection of capsules outside ±5.0% of target fill weight, and process capability is assessed using USP ‹905› content uniformity requirements with an acceptance value (AV) of ≤15.0. Dissolution testing per USP ‹711› employs Apparatus 1 (basket, 100 rpm) or Apparatus 2 (paddle, 50 rpm) in 900 mL of 0.1 N hydrochloric acid, with a Q value of 75% at 45 minutes as a common specification. Compliance with ICH Q3D (R2) for elemental impurities and USP ‹467› for residual solvents is verified on the API before release for encapsulation, and the finished product is tested for microbial limits per USP ‹61› and ‹62›. Terminal dosage forms include 250 mg and 500 mg hard gelatin capsule presentations for oral administration, supplied in PVC/PVdC/aluminum blister packs or HDPE containers with desiccant.

Sulphamethoxypyridazine base is practically insoluble in purified water (approximately 0.15–0.30 mg/mL at 25°C), which dictates that oral granules for reconstitution into suspension are manufactured as sugar-based or sorbitol-based dry blends that generate a uniformly dispersed slurry only upon addition of water at the point of dispensing. The granule formulation is designed to deliver 250 mg of API per 5 mL of reconstituted suspension, with the API incorporated at 5–10% w/w of the total dry granule mass. Excipients include sucrose or sorbitol as the primary bulking and sweetening agent at 60–75% w/w, xanthan gum or sodium carboxymethylcellulose as suspending agent at 0.5–2.0% w/w, sodium benzoate or potassium sorbate as antimicrobial preservative at 0.1–0.2% w/w, citric acid monohydrate as buffering agent at 0.5–1.5% w/w, and a pharmaceutically acceptable flavoring system at 0.1–0.5% w/w. Granulation is performed in a high-shear granulator or fluid bed granulator (Glatt GPCG 30 top-spray configuration) using an aqueous binder solution of PVP K30 at 2.0–4.0% w/w, with inlet air temperature 60–70°C and product temperature maintained below 40°C to prevent thermochromic degradation of the sulfonamide, which is known to undergo light-accelerated and heat-accelerated discoloration. The dried granules are sieved through an oscillating granulator with a 1.2–1.5 mm screen and filled into unit-dose sachets using a form-fill-seal machine or into amber glass bottles with a desiccant-lined closure and a recalibration-free dropper or measuring cup. Reconstitution testing per USP ‹698› verifies deliverable volume, and sedimentation volume after 24 hours of standing is assessed as a suspension quality attribute. Preservative effectiveness is established through USP ‹51› Antimicrobial Effectiveness Testing against Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis, with the acceptance criterion that bacterial counts decline by at least 1.0 log₁₀ within 7 days and fungal counts show no increase from the initial count. The finished granules are tested for content uniformity per USP ‹905› on the unit-dose sachets and for moisture content by USP ‹921› Karl Fischer titration with a specification of ≤2.0% w/w. Terminal product types include 250 mg/5 mL oral suspension granules in single-dose sachets and multidose bottle presentations for pediatric and geriatric patients with dysphagia.

Lyophilization Cycle Design for a Poorly Water-Soluble Sulfonamide at Pilot Scale

The conversion of sulphamethoxypyridazine base into a sterile injectable dosage form is constrained by the API's negligible aqueous solubility at physiological pH and its susceptibility to precipitation under acidic conditions. The base material is solubilized in Water for Injection by addition of 1.0 M sodium hydroxide solution with continuous stirring at 200–400 rpm in a jacketed stainless steel vessel maintained at 15–25°C, producing the water-soluble sodium salt via deprotonation of the sulfonamide nitrogen. The target concentration of sulphamethoxypyridazine as sodium salt equivalent ranges from 100–250 mg/mL expressed as base, corresponding to 10–25% w/v of the formulation. Mannitol is added as a bulking agent at 2.0–5.0% w/v to provide a crystalline lyo-cake matrix, and the pH is adjusted with 1.0 M hydrochloric acid to a final value of 9.0–9.8, which is selected because below pH 8.5 the free base precipitates as insoluble crystalline sulphamethoxypyridazine and above pH 10.5 accelerated hydrolytic cleavage of the sulfonamide linkage becomes measurable by HPLC. The solution is pre-filtered through a 0.45 µm polyethersulfone membrane and then sterile-filtered through two 0.22 µm polyvinylidene fluoride membrane filters in series, with filter integrity testing performed by bubble point and diffusive flow methods per USP ‹71› Sterility Tests and EU GMP Annex 1 (2022 revision) section 8.87 on filter integrity. Aseptic filling into Type I borosilicate glass vials (2R, 5R, or 10R) is conducted in a Grade A/ISO 5 environment under Grade B/ISO 7 background using a peristaltic pump with disposable tubing and a fill volume of 2.0–20.0 mL depending upon final label claim. The filled vials are partially stoppered with bromobutyl lyophilization stoppers and transferred to a freeze dryer with shelf temperature control. The lyophilization cycle is designed around the collapse temperature of the mannitol–sodium sulphamethoxypyridazine matrix, which is measured by freeze-drying microscopy; typical collapse onset occurs between -30°C and -25°C, dictating a primary drying shelf temperature of -25 to -20°C at a chamber pressure of 100–200 mTorr (13–27 Pa). Freezing is conducted at -40 to -45°C for 3–5 hours, followed by primary drying for 18–30 hours and secondary drying at +25 to +35°C for 6–12 hours, with product temperature monitored via thermocouples and Pirani gauge versus capacitance manometer readings used to detect the end of primary drying. The finished lyophilized cake is inspected for particulate matter per USP ‹788› Particulate Matter in Injections (light obscuration method) and USP ‹790› Visible Particulates in Injections, tested for bacterial endotoxins per USP ‹85› with a limit of ≤0.25 EU/mg of sulphamethoxypyridazine, and subjected to sterility testing per USP ‹71› using the membrane filtration method. Residual moisture in the cake is determined by USP ‹921› Karl Fischer titration with a specification of ≤2.5% w/w. Photostability data for the reconstituted solution indicate significant degradation under ICH Q1B light exposure (overall illumination 1.2 million lux-hours, near-UV energy 200 watt-hours/m²), so the final container is an amber vial, and the product is stored protected from light at 15–25°C. Terminal dosage forms include 500 mg and 1 gram lyophilized powder for solution for injection, reconstituted with Sterile Water for Injection to a concentration of 100–250 mg/mL for slow intravenous infusion or deep intramuscular injection. Published data for this specific configuration is limited, and formulation development batches should prospectively validate the lyophilization cycle with product temperature mapping and residual moisture data generated on the actual freeze dryer to be used for commercial production.

Veterinary Bolus Compression and Rumen Disintegration Kinetics

Sulphamethoxypyridazine base is formulated into large oblong veterinary boluses for oral administration to cattle, sheep, and goats, where the dose ranges from 30–60 mg/kg body weight depending on the infectious indication and regional prescribing guidelines. Bolus compression differs from conventional tablet compression in that the API is dry granulated by roller compaction (Alexanderwerk WP 120 or Fitzpatrick CCS 220) because wet granulation of high-dose sulfonamide formulations produces over-granulated ribbons that break into particles with excessive fines generation, reducing subsequent die filling efficiency. The API fraction in the bolus core typically spans 25–50% w/w, with microcrystalline cellulose or dicalcium phosphate dihydrate as filler at 30–50% w/w, sodium starch glycolate at 2.0–4.0% w/w as disintegrant, and magnesium stearate at 0.5–1.0% w/w as lubricant. Compression is performed on a heavy-duty single-station or rotary tablet press designed for large tooling (oblong punches of 18–22 mm tip length and 9–12 mm tip width), with compression force calibrated to produce a crushing strength of 120–200 N measured across the bolus long axis. The disintegration test for boluses does not follow human pharmacopeial apparatus because of the size exclusion from USP ‹701›; dissolution testing is conducted instead in USP ‹711› Apparatus 2 at 75–100 rpm using 900 mL of pH 5.8 acetate buffer or dilute hydrochloric acid (0.1 N) to approximate rumen and abomasal fluid conditions. Rumen retention and dissolution are influenced by bolus density, with an acceptable density range of 1.10–1.30 g/cm³ to prevent regurgitation while allowing gradual sink into the rumen liquor. The finished bolus is tested for residual solvents per VICH GL18(R2), for related substances per VICH GL11, and for release under the veterinary medicinal product quality requirements of EU Regulation 2019/6 Article 93 and 21 CFR Part 514 where applicable. Terminal products include 500 mg, 1 gram, and 2 gram sulphamethoxypyridazine boluses, individually packed in peelable aluminum foil blisters to prevent moisture uptake, which above 60% RH causes softening and loss of mechanical integrity of the bolus core.

When Trimethoprim Co-formulation Alters Dissolution Profile at pH 1.2

The combination of sulphamethoxypyridazine base and trimethoprim at a fixed 5:1 ratio (for example, 400 mg sulphamethoxypyridazine plus 80 mg trimethoprim per tablet) introduces measurable dissolution interference that does not occur in single-component formulations, because trimethoprim is a weak base with pH-dependent solubility that partitions differently from the sulfonamide across the pH range of 1.2–6.8. At pH 1.2 both actives dissolve relatively rapidly, but at pH 4.5 acetate buffer the dissolution rate of trimethoprim declines sharply while sulphamethoxypyridazine remains ionized in its sodium-form microclimate, creating a divergent release profile that necessitates formulation-level intervention. Granulation for this fixed-dose combination is performed in a high-shear granulator with an aqueous PVP K30 binder solution at 2.0–5.0% w/w, with the API fraction totaling 55–70% w/w of the core mass and filler consisting of lactose monohydrate or microcrystalline cellulose PH101 at 15–30% w/w. Disintegrant selection is critical: croscarmellose sodium at 3.0–5.0% w/w provides rapid tablet disintegration (less than 5 minutes in purified water) and creates microenvironments that partially compensate for the trimethoprim dissolution lag, whereas sodium starch glycolate at equivalent levels produces slower disintegration (10–15 minutes) and fails to achieve the Q value for trimethoprim at early time points in dissolution testing. Compression is performed on a rotary tablet press with 13 mm round tooling at 8–15 kN force, targeting core hardness 70–110 N, and the cores are film-coated with an aqueous HPMC system to 2.0–3.0% w/w weight gain. Dissolution testing follows USP ‹711› Apparatus 2 at 50 rpm in 900 mL of 0.1 N hydrochloric acid (pH 1.2) for both analytes, with acceptance criteria of not less than 75% dissolved at 45 minutes for sulphamethoxypyridazine and not less than 70% for trimethoprim at the same time point, with both analytes quantified by a validated HPLC method using a C18 column and UV detection at 254 nm. Additional dissolution profiling in pH 4.5 acetate buffer and pH 6.8 phosphate buffer is recommended to characterize the formulation across the gastrointestinal pH gradient, and the European Pharmacopoeia 11.0 general chapter 2.9.3 requires dissolution profile comparison (f₂ similarity factor) when proposing scale-up changes. Related substances testing must resolve trimethoprim degradation products, particularly the benzyl pyrimidine oxidative derivatives, using HPLC gradient elution with photodiode array detection per Ph.Eur. 2.2.29. The combination tablet is governed additionally by USP ‹905› for content uniformity of both actives and ICH Q3D (R2) for elemental impurities applied to the blended API-plus-excipient matrix. Terminal product types include 400 mg/80 mg and 500 mg/100 mg fixed-dose combination tablets, positioned primarily in veterinary and select human regional markets where sulphamethoxypyridazine–trimethoprim combinations remain part of national formularies. Operational incompatibility is noted with highly alkaline granulated systems: maintaining granulation moisture above 6.0% w/w during high-shear mixing causes localized hydrolysis of trimethoprim and discoloration of the sulfonamide, so tray drying or fluid bed drying must reduce loss-on-drying to 1.5–2.5% w/w within 45–60 minutes immediately after granulation to prevent this degradation pathway.